These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 28036386)

  • 1. Src Inhibition Can Synergize with Gemcitabine and Reverse Resistance in Triple Negative Breast Cancer Cells via the AKT/c-Jun Pathway.
    Wu ZH; Lin C; Liu MM; Zhang J; Tao ZH; Hu XC
    PLoS One; 2016; 11(12):e0169230. PubMed ID: 28036386
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models.
    Formisano L; Nappi L; Rosa R; Marciano R; D'Amato C; D'Amato V; Damiano V; Raimondo L; Iommelli F; Scorziello A; Troncone G; Veneziani B; Parsons SJ; De Placido S; Bianco R
    Breast Cancer Res; 2014 May; 16(3):R45. PubMed ID: 24887236
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneously inactivating Src and AKT by saracatinib/capivasertib co-delivery nanoparticles to improve the efficacy of anti-Src therapy in head and neck squamous cell carcinoma.
    Lang L; Shay C; Zhao X; Xiong Y; Wang X; Teng Y
    J Hematol Oncol; 2019 Dec; 12(1):132. PubMed ID: 31805962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.
    Nagaraj NS; Washington MK; Merchant NB
    Clin Cancer Res; 2011 Feb; 17(3):483-93. PubMed ID: 21266529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PAI-1 induces Src inhibitor resistance via CCL5 in HER2-positive breast cancer cells.
    Fang H; Jin J; Huang D; Yang F; Guan X
    Cancer Sci; 2018 Jun; 109(6):1949-1957. PubMed ID: 29601121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. miR-19b-3p inhibits breast cancer cell proliferation and reverses saracatinib-resistance by regulating PI3K/Akt pathway.
    Jin J; Sun Z; Yang F; Tang L; Chen W; Guan X
    Arch Biochem Biophys; 2018 May; 645():54-60. PubMed ID: 29550144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antitumor activity of saracatinib (AZD0530), a c-Src/Abl kinase inhibitor, alone or in combination with chemotherapeutic agents in gastric cancer.
    Nam HJ; Im SA; Oh DY; Elvin P; Kim HP; Yoon YK; Min A; Song SH; Han SW; Kim TY; Bang YJ
    Mol Cancer Ther; 2013 Jan; 12(1):16-26. PubMed ID: 23144237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Down-regulation of Rad51 expression overcomes drug resistance to gemcitabine in human non-small-cell lung cancer cells.
    Tsai MS; Kuo YH; Chiu YF; Su YC; Lin YW
    J Pharmacol Exp Ther; 2010 Dec; 335(3):830-40. PubMed ID: 20855443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pERK1/2 silencing sensitizes pancreatic cancer BXPC-3 cell to gemcitabine-induced apoptosis via regulating Bax and Bcl-2 expression.
    Wang M; Lu X; Dong X; Hao F; Liu Z; Ni G; Chen D
    World J Surg Oncol; 2015 Feb; 13():66. PubMed ID: 25880226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cytoprotective role of gemcitabine-induced autophagy associated with apoptosis inhibition in triple-negative MDA-MB-231 breast cancer cells.
    Chen M; He M; Song Y; Chen L; Xiao P; Wan X; Dai F; Shen P
    Int J Mol Med; 2014 Jul; 34(1):276-82. PubMed ID: 24804820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
    Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
    J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer.
    Li T; Tao Z; Zhu Y; Liu X; Wang L; Du Y; Cao J; Wang B; Zhang J; Hu X
    Cell Death Dis; 2021 Jul; 12(7):684. PubMed ID: 34238922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Src family kinase oncogenic potential and pathways in prostate cancer as revealed by AZD0530.
    Chang YM; Bai L; Liu S; Yang JC; Kung HJ; Evans CP
    Oncogene; 2008 Oct; 27(49):6365-75. PubMed ID: 18679417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of pancreatic cancer cell apoptosis, invasion, migration, and enhancement of chemotherapy sensitivity of gemcitabine, 5-FU, and oxaliplatin by hnRNP A2/B1 siRNA.
    Gu WJ; Liu HL
    Anticancer Drugs; 2013 Jul; 24(6):566-76. PubMed ID: 23525071
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting X-linked inhibitor of apoptosis protein inhibits pancreatic cancer cell growth through p-Akt depletion.
    Jiang C; Yi XP; Shen H; Li YX
    World J Gastroenterol; 2012 Jun; 18(23):2956-65. PubMed ID: 22736919
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of using prodrug-modified cationic liposome nanocomplexes and a potentiating strategy via targeted co-delivery of gemcitabine and docetaxel for CD44-overexpressed triple negative breast cancer therapy.
    Fan Y; Wang Q; Lin G; Shi Y; Gu Z; Ding T
    Acta Biomater; 2017 Oct; 62():257-272. PubMed ID: 28859899
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual ErbB1 and ErbB2 receptor tyrosine kinase inhibition exerts synergistic effect with conventional chemotherapy in pancreatic cancer.
    Singla S; Pippin JA; Drebin JA
    Oncol Rep; 2012 Dec; 28(6):2211-6. PubMed ID: 23007710
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination therapy with gossypol reveals synergism against gemcitabine resistance in cancer cells with high BCL-2 expression.
    Wong FY; Liem N; Xie C; Yan FL; Wong WC; Wang L; Yong WP
    PLoS One; 2012; 7(12):e50786. PubMed ID: 23226540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
    Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
    Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.